Valuation : Linc AB

Market Cap 4.29B 449M 386M 362M 332M 619M 42.43B 624M 1.67B 21.69B 1.69B 1.65B 69.84B P/E 2024
3.84x
P/E 2025 -10.1x
Enterprise Value 4B 419M 361M 338M 310M 578M 39.62B 583M 1.56B 20.25B 1.57B 1.54B 65.22B EV / Sales 2024
3.45x
EV / Sales 2025 -9.06x
Free-Float
38.31%
Yield 2024 *
-
Yield 2025 -
1 day+1.51%
1 week-1.07%
Current month+1.51%
1 month-0.54%
3 months+4.66%
6 months+12.61%
Current year+6.31%
1 week 72.2
Extreme 72.2
75.6
1 month 71.7
Extreme 71.7
76
Current year 58.9
Extreme 58.9
78.1
1 year 58.9
Extreme 58.9
78.1
3 years 52.2
Extreme 52.2
103.4
5 years 43.8
Extreme 43.8
103.4
10 years 43.8
Extreme 43.8
118.2
Manager TitleAgeSince
Chief Executive Officer 52 01/01/2020
Director of Finance/CFO 44 01/01/2020
Director TitleAgeSince
Chairman 73 01/01/1991
Director/Board Member 52 01/01/2020
Director/Board Member 60 01/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
06/08/26 Buy

Chief Executive Officer

5,000 0.0086%
30/04/26 Buy

Director

3,516 0.0061%
30/04/26 Buy

Director

8,484 0.0147%
Change 5-day change 1-year change 3-year change Capi.($)
+1.51%-1.07%-3.26%+14.53% 439M
+1.27%+1.27%+15.94%+4.58% 170M
Average +1.39%+0.15%+6.34%+9.55% 304.72M
Weighted average by Cap. +1.44%-0.63%+2.11%+11.75%

Financials

2024 2025
Net sales 1.29B 135M 116M 109M 99.86M 186M 12.78B 188M 503M 6.53B 508M 497M 21.03B -414M -43.34M -37.29M -35M -32.02M -59.76M -4.1B -60.24M -161M -2.09B -163M -159M -6.74B
Net income 1.3B 136M 117M 110M 101M 188M 12.88B 189M 507M 6.58B 512M 501M 21.2B -400M -41.84M -36M -33.78M -30.91M -57.69M -3.96B -58.15M -156M -2.02B -157M -154M -6.51B
Net Debt -550M -57.55M -49.51M -46.46M -42.51M -79.34M -5.44B -79.97M -214M -2.78B -216M -211M -8.95B -284M -29.73M -25.58M -24.01M -21.96M -40.99M -2.81B -41.32M -111M -1.44B -112M -109M -4.63B
Logo Linc AB
Linc AB is a Sweden-based investment company. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The Company works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.
Employees
2
Date Price Change Volume
03/09/26 SEK 74.10 +1.51% 32,259
02/09/26 SEK 73.00 +0.41% 35,697
01/09/26 SEK 72.70 -0.41% 37,264
31/08/26 SEK 73.00 -3.18% 34,988
28/08/26 SEK 75.40 +0.67% 38,251
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
74.10SEK
Average target price
72.00SEK
Spread / Average Target
-2.83%
  1. Stock Market
  2. Stocks
  3. LINC Stock